HomeCompareNPPNY vs GIS

NPPNY vs GIS: Dividend Comparison 2026

NPPNY yields 2.84% · GIS yields 6.53%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NPPNY wins by $79.5K in total portfolio value· pulled ahead in Year 7
10 years
NPPNY
NPPNY
● Live price
2.84%
Share price
$7.40
Annual div
$0.21
5Y div CAGR
47.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$158.3K
Annual income
$65,881.22
Full NPPNY calculator →
GIS
GIS
● Live price
6.53%
Share price
$37.22
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.8K
Annual income
$16,211.26
Full GIS calculator →

Portfolio growth — NPPNY vs GIS

📍 NPPNY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPPNYGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPPNY + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPPNY pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPPNY
Annual income on $10K today (after 15% tax)
$241.22/yr
After 10yr DRIP, annual income (after tax)
$55,999.04/yr
GIS
Annual income on $10K today (after 15% tax)
$554.94/yr
After 10yr DRIP, annual income (after tax)
$13,779.57/yr
At 15% tax rate, NPPNY beats the other by $42,219.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPPNY + GIS for your $10,000?

NPPNY: 50%GIS: 50%
100% GIS50/50100% NPPNY
Portfolio after 10yr
$118.6K
Annual income
$41,046.24/yr
Blended yield
34.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

NPPNY
No analyst data
Altman Z
6.7
Piotroski
5/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.4% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPPNY buys
0
GIS buys
0
No recent congressional trades found for NPPNY or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPPNYGIS
Forward yield2.84%6.53%
Annual dividend / share$0.21$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR47.7%22.8%
Portfolio after 10y$158.3K$78.8K
Annual income after 10y$65,881.22$16,211.26
Total dividends collected$128.1K$50.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NPPNY vs GIS ($10,000, DRIP)

YearNPPNY PortfolioNPPNY Income/yrGIS PortfolioGIS Income/yrGap
1$11,119$419.15$11,502$801.73$383.00GIS
2$12,541$643.33$13,365$1,058.29$824.00GIS
3$14,420$1,001.58$15,712$1,411.34$1.3KGIS
4$17,019$1,589.76$18,716$1,904.17$1.7KGIS
5$20,801$2,590.00$22,629$2,603.16$1.8KGIS
6$26,626$4,369.50$27,826$3,612.21$1.2KGIS
7← crossover$36,211$7,720.76$34,871$5,097.54+$1.3KNPPNY
8$53,240$14,493.90$44,643$7,331.52+$8.6KNPPNY
9$86,382$29,415.55$58,541$10,772.15+$27.8KNPPNY
10$158,310$65,881.22$78,850$16,211.26+$79.5KNPPNY

NPPNY vs GIS: Complete Analysis 2026

NPPNYStock

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Full NPPNY Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this NPPNY vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPPNY vs SCHDNPPNY vs JEPINPPNY vs ONPPNY vs KONPPNY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.